Immunotherapy with Dialyzable Leukocyte Extracts Containing Transfer Factor

Arnaudov, A.

doi:10.5772/66524

Cited by 6 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several patented processes for DLE production are available, including a human derived DLE [17]. Administration of DLE has been reported as an effective adjuvant in the treatment of infections, allergies, cancer, and immunodeficiencies [18]. DLE ability to modulate immune responses has been defined in several reviews as due to immune activator and suppressor properties.…”

Section: Introductionmentioning

confidence: 99%

Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

Vázquez

Reséndiz-Albor

Ynga-Durand

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

Vázquez

Reséndiz-Albor

Ynga-Durand

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Therefore, TF gives attractive option to complement chemotherapy, which might strengthen immune system after disturbances following chemotherapy side effects [3,48,49]. Main TF benefit as immunotherapeutic agents is possibility to stimulate rapid immune reaction against pathogen within 24 hours and reducetime for patient immune response to 9-13 days [50]. Combination of results from different TF studies in one and extracting treatment outcomes of cancer with chemotherapy, autoimmune disorders, allergies also immunodefficiencies and infection diseases can be used by clinicians for decision-making and improving patient's life quality.…”

Section: Methodsmentioning

confidence: 99%

Untitled

2019

Int J Immunol Immunother

View full text Add to dashboard Cite

Immune Modulating Peptides (IMP) discussed in literature as a universal immunocorrectors with wide areas of usage which balance the immune system without causing global immune suppression or overreaction. The present article aim is to review the effect and drawbacks of IMPs in form of Dialyzable leukocyte Extracts (DLE) or Transfer Factors (TF) during and following chemotherapy, radiotherapy, drugs interactions, cancer response and clinical outcomes in different cases of cancers such as metastatic breast cancer, glioma, prostate cancer, osteosarcoma and others. The considered cases of immune overreaction and IMP's impact include autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and allergic reactions. The most difficult therapeutic decision is to choose the right treatment for patients with cancer and autoimmune diseases as they both attempt to supervise and control the immune system, managing immune cells in opposite sides. As patients with autoimmune disease experience difficulty to stay in such treatment when immune cells stimulated in order to identify and destroy cancer cells the IMP as immunocorrectors become one of the main and only healthy choices. The universal mechanism of IMPs action and the absence of contraindications extend the indications for their use in pediatric practice. This includes the complex treatment of respiratory viral infections, the possibility of using in frequently ill children with clinical signs of immune dysfunction and acute intestinal infections. According to the reports on safety, absence of adverse and side effects along with positive outcome for patients the IMPs considered as valuable immunocorrector.

show abstract

“…This group includes substances produced by immune system cells, also known as dialysable leukocyte extracts (DLE). DLE are a diverse mixture of low-molecular weight compounds derived from blood or lymphoid tissue with immunomodulatory properties (153). Several reports have shown that DLE derived from human blood or lymphoid tissue from different animals (crocodile, porcine or bovine) can regulate numerous molecular targets, thereby facilitating immunomodulatory effects in conditions such as autoimmune diseases, immunodeficiencies, asthma, bacterial infections and certain types of cancer (153)(154)(155)(156).…”

Section: Other Immunomodulators 451 Biological Immunomodulatorsmentioning

confidence: 99%

Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system

Calvillo-Rodríguez,

Lorenzo-Anota,

Rodríguez-Padilla

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Cancer immunotherapies include monoclonal antibodies, cytokines, oncolytic viruses, cellular therapies, and other biological and synthetic immunomodulators. These are traditionally studied for their effect on the immune system’s role in eliminating cancer cells. However, some of these therapies have the unique ability to directly induce cytotoxicity in cancer cells by inducing immunogenic cell death (ICD). Unlike general immune stimulation, ICD triggers specific therapy-induced cell death pathways, based on the release of damage-associated molecular patterns (DAMPs) from dying tumour cells. These activate innate pattern recognition receptors (PRRs) and subsequent adaptive immune responses, offering the promise of sustained anticancer drug efficacy and durable antitumour immune memory. Exploring how onco-immunotherapies can trigger ICD, enhances our understanding of their mechanisms and potential for combination strategies. This review explores the complexities of these immunotherapeutic approaches that induce ICD, highlighting their implications for the innate immune system, addressing challenges in cancer treatment, and emphasising the pivotal role of ICD in contemporary cancer research.

show abstract

Immunotherapy with Dialyzable Leukocyte Extracts Containing Transfer Factor

Cited by 6 publications

References 60 publications

Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

Untitled

Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system

Contact Info

Product

Resources

About